Amyloid-beta- associated clinical decline occurs only in the presence of elevated p-tau
- Author(s): Desikan, Rahul S.
- McEvoy, Linda K.
- Thompson, Wesley K.
- Holland, Dominic
- Brewer, James B.
- Aisen, Paul S.
- Sperling, Reisa A.
- Dale, Anders M.
- et al.
Published Web Locationhttp://www.ncbi.nlm.nih.gov/pmc/articles/PMC3423526/pdf/nihms-378564.pdf
To elucidate the relationship between the two hallmark proteins of Alzheimer's disease (AD), amyloid-β (Aβ) and tau, and clinical decline over time among cognitively normal older individuals.Design
A longitudinal cohort of clinically and cognitively normal older individuals assessed with baseline lumbar puncture and longitudinal clinical assessments.Setting
Research centers across the United States and Canada.Patients
We examined one hundred seven participants with a Clinical Dementia Rating (CDR) of 0 at baseline examination.Main Outcome Measures
Using linear mixed effects models, we investigated the relationship between CSF p-tau181p, CSF Aβ1-42 and clinical decline as assessed using longitudinal change in global CDR, CDR-Sum of Boxes (CDR-SB), and the Alzheimer's Disease Assessment Scale-cognitive subscale (ADAS-cog).Results
We found a significant relationship between decreased CSF Aβ1-42 and longitudinal change in global CDR, CDR-SB, and ADAS-cog in individuals with elevated CSF p-tau181p. In the absence of CSF p-tau181p, the effect of CSF Aβ1-42 on longitudinal clinical decline was not significantly different from zero.Conclusions
In cognitively normal older individuals, Aβ-associated clinical decline over a mean of three years may occur only in the presence of ongoing, “downstream” neurodegeneration.